Business
Mainz Biomed Partners with Liquid Biosciences to Harness the Power of Artificial Intelligence (AI) to Develop Next-generation Colorectal Screening Test
Collaboration to utilize cutting-edge AI analysis platform for clinical trials and cancer screening test processing BERKELEY, Calif. and MAINZ, Germany, Nov.
About this update from Quantum Cyber N.v.
[{"type":"text","content":"Collaboration to utilize cutting-edge AI analysis platform for clinical trials and cancer screening test processing\nBERKELEY, Calif. and MAINZ, Germany, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today a strategic partnership with Liquid Biosciences, a bio-analytics company leveraging its proprietary AI analysis technology platform (EMERGE) to serve the biopharma and diagnostics industries along with academic institutions. The collaboration builds upon Mainz Biomed’s initial utilization of EMERGE to analyze the Company’s ColoFuture study, which recently reported groundbreaking results including sensitivity for colorectal cancer of 94% with a specificity of 97% and a sensitivity for advanced adenoma of 80%. ColoFuture is an international multi-center clinical trial which assessed the potential to integrate a portfolio of novel gene expression (mRNA) biomarkers into ColoAlert®, Mainz Biomed’s highly efficacious, and easy-to-use screening test for colorectal cancer (CRC) being commercialized across Europe and in select international territories. This proprietary family of mRNA biomarkers represents a potentially game-changing innovation in CRC screening as the portfolio has previously demonstrated the ability to detect CRC lesions, including advanced adenomas, a type of pre-cancerous polyp often attributed to this deadly disease. Under the terms of the partnership, the utility of EMERGE in Mainz Biomed’s product development pipeline will be extended to include analysis of its eAArly DETECT study (the U.S. arm of the ColoFuture clinical trial), and the forthcoming U.S. pivotal FDA PMA trial (ReconAAsense) which, if successful, will enable Mainz Biomed to further advance its current test’s capabilities and commercialize a next-generation, gold standard, self-administered CRC screening tool. The eAArly DETECT clinical trial, a multi-center feasibility study is enrolling 265 subjects across 22 sites and remains on track to report results in Q4 2023. The goal at completion will result in a single fixed machine learning/AI-based algorithm, developed utilizing the evolutionary EMERGE platform, integrated into the next-generation product’s test report. “As artificial intelligence continue...